news

DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020

CUPERTINO, Calif., Nov. 13, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today presented additional safety data and efficacy signals from its Phase 1b clinical trial of DUR-928 in nonalcoholic steatohepatitis (NASH) patients in a poster presentation at The AASLD Liver Meeting Digital Experience ™ (TLMdX) 2020. “The additional safety and efficacy data presented, including improvements in […]

DURECT Corporation Announces Additional Safety Data and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020 Read More »

DURECT Corporation to Host Webinar on the Treatment of Alcoholic Hepatitis Featuring Chief Medical Officer Dr. Norman Sussman

CUPERTINO, Calif., Nov. 10, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that Norman Sussman, MD, FAASLD, newly appointed Chief Medical Officer, will host a webinar on the treatment landscape and unmet medical need in treating patients with alcoholic hepatitis (AH), as well as information on DURECT‘ investigational drug candidate, DUR-928, being developed for the treatment

DURECT Corporation to Host Webinar on the Treatment of Alcoholic Hepatitis Featuring Chief Medical Officer Dr. Norman Sussman Read More »

DURECT Corporation Announces Third Quarter 2020 Financial Results and Update of Programs

Webcast of Earnings Call Today, November 2nd at 4:30 p.m. ET CUPERTINO, Calif., Nov. 2, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2020 and provided a corporate update. Total revenues were $2.7 million and net loss was $9.3 million for the three months ended

DURECT Corporation Announces Third Quarter 2020 Financial Results and Update of Programs Read More »

DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer

CUPERTINO, Calif., Nov. 2, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on the development of treatments for acute organ injury and chronic liver diseases, today announced it has appointed Norman Sussman, M.D. as its Chief Medical Officer, effective immediately. In this new role, Dr. Sussman will oversee the clinical development of

DURECT Corporation Appoints Dr. Norman Sussman as Chief Medical Officer Read More »

DURECT Corporation to Announce Third Quarter 2020 Financial Results and Provide Business Update on November 02, 2020

CUPERTINO, Calif., Oct. 27, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will report third quarter 2020 financial results and host a conference call after the market close on Monday, November 2, 2020. Monday, November 2 @ 4:30pm Eastern Time / 1:30 p.m. Pacific TimeToll Free:                             877-407-0784International:                        201-689-8560Conference ID:                    13712508Webcast:                              http://public.viavid.com/index.php?id=142231 About DURECT Corporation DURECT is a biopharmaceutical

DURECT Corporation to Announce Third Quarter 2020 Financial Results and Provide Business Update on November 02, 2020 Read More »

DURECT Corporation to Participate in the ROTH Capital Partners Healthcare Event “Covid-19 Therapeutics in Development”

CUPERTINO, Calif., Oct. 26, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced that it will partipate in the ROTH Capital Healthcare Event, “Covid-19 Therapeutics in Development,” taking place on Wednesday, October 28, 2020.  The ROTH Healthcare and Biotechnology team are hosting the webinar to discuss key therapies in development to treat COVID disease.  The Webinar

DURECT Corporation to Participate in the ROTH Capital Partners Healthcare Event “Covid-19 Therapeutics in Development” Read More »

DURECT Corporation to Present Additional Safety and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020

CUERTINO, Calif., Oct. 5, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it will present a poster at The AASLD Liver Meeting Digital Experience ™ (TLMdX) 2020, to be held virtually on November 13-16, 2020.  Topline results from the 4-week Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients were released previously,

DURECT Corporation to Present Additional Safety and Efficacy Signals from Phase 1b Clinical Trial of DUR-928 in NASH Patients at The Liver Meeting Digital Experience™ 2020 Read More »

DURECT Corporation to Participate in Fireside Chat at H.C. Wainwright 4th Annual NASH Investor Conference

CUPERTINO, Calif., Sept. 30, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown, President, CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. WeiQi Lin, Executive Vice President of R&D will be participating in a fireside chat hosted by Ed Arce of H. C. Wainwright on Monday, October 5, 2020 from

DURECT Corporation to Participate in Fireside Chat at H.C. Wainwright 4th Annual NASH Investor Conference Read More »

DURECT Corporation Announces First Patient Dosed in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury

CUPERTINO, Calif., Sept. 23, 2020 /PRNewswire/ — DURECT Corporation (Nasdaq: DRRX) today announced it has dosed the first patient in its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of survival

DURECT Corporation Announces First Patient Dosed in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury Read More »

DURECT Corporation Announces Design of Phase 2b AH Study (AHFIRM)

Phase 2b study in subjects with Alcoholic Hepatitis to evaluate safety and efFIcacy of DUR-928 treatMent (AHFIRM) CUPERTINO, Calif., Sept. 22, 2020 /PRNewswire/ — DURECT Corporation (NASDAQ: DRRX) today announced the study design for the Phase 2b AHFIRM clinical trial of DUR-928 in severe alcoholic hepatitis (AH) patients. AHFIRM is a randomized, double-blind, placebo-controlled, international, multi-center

DURECT Corporation Announces Design of Phase 2b AH Study (AHFIRM) Read More »

Scroll to Top